Abstract #0726
The Transfer Constant K trans in Glioblastomas is Limited by Permeability and not Perfusion
Atle Bjornerud 1,2 , A. Gregory Sorensen 3,4 , Patrick Y Wen 5 , Tracy T Batchelor 6,7 , Rakesh K Jain 6 , and Kyrre E Emblem 1,3
1
The Intervention Centre, Oslo University
Hospital, Oslo, Norway,
2
Dept
of Physics, University of Oslo, Oslo, Norway,
3
Department
of Radiology and Athinoula A. Martinos Center for
Biomedical Imaging, Massachusetts General Hospital and
Harvard Medical School, Boston, Massachusetts, United
States,
4
Siemens
Healthcare Health Services, Pennsylvania, United States,
5
Center
for Neuro-Oncology, Dana-Farber/Brigham and Womens
Cancer Center and Harvard Medical School, Massachusetts,
United States,
6
Department
of Radiation Oncology, Massachusetts General Hospital
and Harvard Medical School, Massachusetts, United
States,
7
Department
of Neurology, Massachusetts General Hospital and Harvard
Medical School, Massachusetts, United States
Tumor perfusion (CBF) and capillary permeability
transfer constant (Ktrans) have been proposed as
sensitive biomarkers to monitor the effect of
vascular-targeting and anti-angiogenic agents. Possible
inter-dependence of these two metrics may, however
complicate their interpretation in clinical data. We
used dynamic susceptibility contrast (DSC) MRI to
estimate both CBF, Ktrans and the initial contrast agent
extraction fraction (E) in 30 patients with recurrent
glioblastomas undergoing anti-angiogenic treatment. The
results suggest that E is on average below 10% in this
patient group and hence Ktrans and CBF can be considered
independent parameters in glioblastomas.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
